Geoffrey Shouse

3.3k total citations
71 papers, 664 citations indexed

About

Geoffrey Shouse is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Geoffrey Shouse has authored 71 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 40 papers in Pathology and Forensic Medicine and 19 papers in Genetics. Recurrent topics in Geoffrey Shouse's work include Lymphoma Diagnosis and Treatment (40 papers), CAR-T cell therapy research (34 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Geoffrey Shouse is often cited by papers focused on Lymphoma Diagnosis and Treatment (40 papers), CAR-T cell therapy research (34 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Geoffrey Shouse collaborates with scholars based in United States, Switzerland and South Africa. Geoffrey Shouse's co-authors include Xin Cai, Xuan Liu, Heng‐Hong Li, Landon G. Piluso, Xuan Liu, Chien-Shing Chen, Rosalia de Necochea-Campion, Saied Mirshahidi, Alexey V. Danilov and Liana Nikolaenko and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Geoffrey Shouse

57 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Geoffrey Shouse United States	14	387	328	139	73	73	71	664
Scott A. Ezell United States	10	339 0.9×	146 0.4×	121 0.9×	89 1.2×	76 1.0×	11	552
Tetsuya Otsuki Japan	11	383 1.0×	155 0.5×	156 1.1×	51 0.7×	56 0.8×	24	561
Anka Bric United States	6	470 1.2×	258 0.8×	99 0.7×	49 0.7×	98 1.3×	6	629
Luhong Sun United States	10	286 0.7×	213 0.6×	207 1.5×	146 2.0×	127 1.7×	19	564
Holger Kohlhammer Germany	9	393 1.0×	203 0.6×	185 1.3×	103 1.4×	129 1.8×	11	721
Francesco Boccalatte United States	12	536 1.4×	193 0.6×	102 0.7×	71 1.0×	156 2.1×	21	804
Piotr Grabarczyk Germany	16	336 0.9×	191 0.6×	99 0.7×	62 0.8×	224 3.1×	36	663
Bandana Sharma United States	8	662 1.7×	283 0.9×	51 0.4×	34 0.5×	41 0.6×	16	833
Lori Berk United States	15	535 1.4×	240 0.7×	85 0.6×	69 0.9×	24 0.3×	20	785
Junli Yan Singapore	12	536 1.4×	171 0.5×	141 1.0×	29 0.4×	193 2.6×	22	786

Countries citing papers authored by Geoffrey Shouse

Since Specialization

Citations

This map shows the geographic impact of Geoffrey Shouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Shouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Shouse more than expected).

Fields of papers citing papers by Geoffrey Shouse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey Shouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Shouse. The network helps show where Geoffrey Shouse may publish in the future.

Co-authorship network of co-authors of Geoffrey Shouse

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey Shouse. A scholar is included among the top collaborators of Geoffrey Shouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey Shouse. Geoffrey Shouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shouse, Geoffrey, Lu Chen, D. Lynne Smith, et al.. (2025). Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leukemia & lymphoma. 66(14). 2790–2793.

Locke, Frederick L., Javier Muñoz, Michael Tees, et al.. (2025). Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. Journal of Clinical Oncology. 43(14). 1695–1705. 11 indexed citations

Epperla, Narendranath, Geoffrey Shouse, Jess Hatfield, et al.. (2025). Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study. Blood. 146(Supplement 1). 4534–4534.

Shouse, Geoffrey, Leslie Popplewell, Tanya Siddiqi, et al.. (2025). Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial. Haematologica. 111(1). 259–270.

Xiao, Annie, Lu Chen, Matthew Mei, et al.. (2025). Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leukemia & lymphoma. 66(12). 2260–2268.

Niu, Jiaxin, Ruth Perets, Solange Peters, et al.. (2024). The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncology. 20(27). 1983–1991. 8 indexed citations

Reid, J., Winston Lee, Joo Y. Song, et al.. (2024). Epstein-Barr virus–positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature. American Journal of Clinical Pathology. 163(2). 298–312.

Lossos, Izidore S., Geoffrey Shouse, Alvaro J. Alencar, et al.. (2024). Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study. Blood. 144(Supplement 1). 3032–3032. 2 indexed citations

Bhaskar, Shakthi, Babatunde Adedokun, Olalekan O. Oluwole, et al.. (2024). Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report. Blood. 144(Supplement 1). 527–527. 2 indexed citations

10.

Goldsmith, Scott, Geoffrey Shouse, F. Lennie Wong, et al.. (2024). Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy. Transplantation and Cellular Therapy. 30(9). 927.e1–927.e9. 5 indexed citations

11.

Shouse, Geoffrey, et al.. (2023). Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma. Blood Reviews. 61. 101099–101099. 2 indexed citations

12.

Goldsmith, Scott, Geoffrey Shouse, F. Lennie Wong, et al.. (2023). Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood. 142(Supplement 1). 4814–4814.

13.

Liu, Tingting, Tycel Phillips, Geoffrey Shouse, et al.. (2023). T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia. Molecular Cancer Therapeutics. 22(9). 1040–1051. 8 indexed citations

14.

Epperla, Narendranath, Geoffrey Shouse, Natalie S. Grover, et al.. (2023). Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. Blood. 142(Supplement 1). 5147–5147.

15.

Ong, Shin Yeu, Matthew Mei, Leslie Popplewell, et al.. (2023). Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma. American Journal of Hematology. 98(11). 1751–1761. 17 indexed citations

16.

Epperla, Narendranath, Qiuhong Zhao, Tamara K. Moyo, et al.. (2023). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Advances. 8(3). 549–552.

17.

Munshi, Pashna N., Yue Chen, Kwang Woo Ahn, et al.. (2022). Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 28(8). 487.e1–487.e7. 11 indexed citations

18.

Liu, Tingting, Xiaoguang Wang, Tamilla Nechiporuk, et al.. (2022). Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. Cell Death and Disease. 13(3). 246–246. 15 indexed citations

19.

Shouse, Geoffrey, et al.. (2013). B56γ Tumor-Associated Mutations Provide New Mechanisms for B56γ-PP2A Tumor Suppressor Activity. Molecular Cancer Research. 11(9). 995–1003. 27 indexed citations

20.

Shouse, Geoffrey, et al.. (2010). A B56γ mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene. 29(27). 3933–3941. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact